Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation
Stenger E, Krishnamurti L, Galipeau J. Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation. BMC Immunology 2015, 16: 74. PMID: 26674007, PMCID: PMC4681052, DOI: 10.1186/s12865-015-0135-7.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationMesenchymal stromal cellsCell transplantationPost-hematopoietic cell transplantationStromal cellsHematopoietic stem cell engraftmentPre-clinical studiesStem cell engraftmentHost diseaseImmune reconstitutionClinical trialsAnimal modelsCell engraftmentMultipotent progenitor cellsImmune systemHSC engraftmentCellular therapyProgenitor cellsTransplantationEngraftmentTrialsDual effectCellsEarly evidenceGVHDRandomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use
Telen M, Wun T, McCavit T, De Castro L, Krishnamurti L, Lanzkron S, Hsu L, Smith W, Rhee S, Magnani J, Thackray H. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood 2015, 125: 2656-2664. PMID: 25733584, PMCID: PMC4408290, DOI: 10.1182/blood-2014-06-583351.Peer-Reviewed Original ResearchConceptsVaso-occlusive crisisSickle cell diseaseComposite primary end pointPrimary end pointPhase 2 studyEnd pointRandomized phase 2 studySCD vaso-occlusive crisisOpioid analgesic useSecondary end pointsActive treatment groupPhase 3 studyVaso-occlusive eventsAnalgesic usePlacebo groupProspective multicenterStudy drugAdverse eventsOpioid useSymptom reliefMedian timeSCD patientsCell diseaseTreatment groupsAnimal models